Melanoma-associated antigen 4 · SINGLE PROTEIN · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-13Melanoma-associated antigen 4 shows approved-linked disease relevance led by synovial sarcoma. 1 more disease program remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P43358. Start with synovial sarcoma, then reuse UniProt P43358 as the stable protein anchor across project notes and exports.
Start with synovial sarcoma, then reuse UniProt P43358 as the stable protein anchor across project notes and exports.
Melanoma-associated antigen 4 shows approved-linked disease relevance led by synovial sarcoma. 1 more disease program remain visible in the same review block. 1 linked drug remains visible in the same block.
Start review with synovial sarcoma because it currently carries approved-linked support. Linked drugs include AFAMITRESGENE AUTOLEUCEL. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyMelanoma-associated antigen 4
Review this target as Melanoma-associated antigen 4, mapped to UniProt P43358. Sequence length is 317 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Melanoma-associated antigen 4 as ChEMBL target CHEMBL4296022, mapped to UniProt P43358. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Melanoma-associated antigen 4 is the right protein anchor across sources, using UniProt P43358 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why synovial sarcoma is currently framed as approved-linked support. It currently carries 1 linked drug in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Melanoma-associated antigen 4 |
| Target Type | SINGLE PROTEIN |
| Organism | Homo sapiens |
| UniProt | P43358 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Melanoma-associated antigen 4 |
| UniProt Accession | P43358 |
| Component Type | Protein |
| Sequence Length | 317 aa |
Melanoma-associated antigen 4
Review this target as Melanoma-associated antigen 4, mapped to UniProt P43358. Sequence length is 317 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Melanoma-associated antigen 4 shows approved-linked disease relevance led by synovial sarcoma. 1 more disease program remain visible in the same review block.
Start review with synovial sarcoma because it currently carries approved-linked support. Linked drugs include AFAMITRESGENE AUTOLEUCEL. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL5199001 | 8.9 | IC50 | 1.26 | Preclinical |
| CHEMBL5188210 | 8.67 | IC50 | 2.15 | Preclinical |
| CHEMBL5187815 | 8.19 | Kd | 6.5 | Preclinical |
| CHEMBL5188210 | 8.01 | Kd | 9.7 | Preclinical |
| CHEMBL5208958 | 7.97 | IC50 | 10.6 | Preclinical |
| CHEMBL5182108 | 7.86 | IC50 | 13.9 | Preclinical |
| CHEMBL5199001 | 7.32 | Kd | 47.4 | Preclinical |
| CHEMBL5197762 | 7.17 | IC50 | 67.5 | Preclinical |
| CHEMBL5187977 | 6.99 | IC50 | 103.1 | Preclinical |
| CHEMBL5175619 | 6.83 | IC50 | 147.55 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| assay format | 15 | 14 | 7.1 |
| cell-based format | 1 | 0 | — |